Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4):364-70

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  FOCUS ON 64CU: RADIOPHARMACEUTICALS AND CLINICAL APPLICATIONS Freefree

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4):364-70

DOI: 10.23736/S1824-4785.20.03311-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Peptide and pseudo-peptide

Siroos MIRZAEI 1 , Rainer W. LIPP 2

1 Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna, Austria; 2 Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria



In recent years, the introduction of theranostic twins for specific diagnosis and treatment in patients with neuroendocrine tumors became a nuclear medicine success story. 64Cu/18F labeled prostate specific membrane antigen (PSMA) for molecular imaging with PET-CT and peptide radioligand therapy with 177Lu labeled PSMA inhibitors will favorably become the next theranostic twins in nuclear medicine history. 68Ga/ 64Cu/18F PSMA PET/CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity. In addition, it can be used to select patients for radioligand therapy and evaluate therapy response. 64Cu-labeled radiopharmaceuticals such as 64Cu-PSMA, and 64Cu-somatostatin analogs are promising imaging tools in the assessment of primary disease and also in the detection of disease recurrence and to evaluate therapy response. The long half-life of 64Cu allows the distribution of the tracer to PET centers as a satellite concept, who otherwise has no access to 68Ga generators.


KEY WORDS: Positron emission tomography computed tomography; Copper-64; Radiopharmaceuticals

inizio pagina